MBX Biosciences, Inc.
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 13.14% | 38.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 50.12% | 5.70% | |||
| Operating Income | -50.12% | -5.70% | |||
| Income Before Tax | -57.74% | -6.60% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -57.74% | -6.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -57.74% | -6.60% | |||
| EBIT | -50.12% | -5.70% | |||
| EBITDA | -50.19% | -5.70% | |||
| EPS Basic | -54.03% | -2.68% | |||
| Normalized Basic EPS | -50.36% | 9.59% | |||
| EPS Diluted | -54.03% | -2.68% | |||
| Normalized Diluted EPS | -50.36% | 9.59% | |||
| Average Basic Shares Outstanding | 2.41% | 3.81% | |||
| Average Diluted Shares Outstanding | 2.41% | 3.81% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||